← Back to All Filings

CSTL COO Sells $317K in Stock Under Pre-Arranged Trading Plan

Low SignificanceNovember 4, 2025 at 9:02:09 PM EST

CASTLE BIOSCIENCES INC

$CSTL4CIK: 0001447362

Subscribe to track CSTL

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

CSTL COO Sells $317K in Stock Under Pre-Arranged Trading Plan

Company: CASTLE BIOSCIENCES INC (CSTL) Form: 4 | Filed: 2025/11/04 Significance: Low

Insider: Oelschlager Kristen M Title: Chief Operating Officer | Relationship: Officer

Transaction: • Type: Sale • Shares: 12,678 • Price: $25.04 • Value: $317,457 • Owned After: 128,506

Key Insight: This sale was executed under a Rule 10b5-1 trading plan established in March 2025, indicating it was pre-scheduled and not necessarily a reaction to recent events. The transaction size is minor relative to the company's market cap.

Market Context: The transaction represents less than 0.05% of the company's market capitalization and shares outstanding, classifying it as a low-significance event.

View Full Filing

Comprehensive Analysis

SEC Filing Analysis: CASTLE BIOSCIENCES INC (CSTL)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The Chief Operating Officer sold $317k worth of stock under a pre-arranged 10b5-1 trading plan, indicating a planned liquidation rather than a spontaneous decision based on current company performance.
  • Market Impact: The transaction is too small to have a material impact on the stock.

Company Information

FieldValue
CompanyCASTLE BIOSCIENCES INC
Ticker SymbolCSTL
CIK0001447362
IndustrySERVICES-MEDICAL LABORATORIES

Insider Information

FieldValue
NameOelschlager Kristen M
CIK0001856565
Title/PositionChief Operating Officer
RelationshipOfficer

Transaction Details

FieldValue
Form Type4
Transaction Date2025-10-31
Transaction CodeS (Sale)
Security TypeCommon Stock
Shares Involved12,678
Price Per Share$25.04
Total Value$317,457.12
Shares Owned After128,506 (Direct & Indirect)
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$317,457.12
% of Market Cap0.043%
Shares Transacted12,678
% of Shares Outstanding0.044%
Post-Transaction Ownership128,506 shares (0.44% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a company with a market capitalization of $740 million, this $317k transaction is financially immaterial.
  • Ownership Concentration: The sale represented approximately 9% of the insider's total holdings. While not insignificant for the individual, her post-transaction ownership of 0.44% remains a small fraction of the total shares outstanding.
  • Transaction Significance: The transaction's value is less than 0.1% of the market cap and the shares involved are less than 0.1% of shares outstanding, placing it firmly in the 'Low' significance category.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The sale is minor in scale and was conducted under a pre-scheduled 10b5-1 plan, which negates any strong negative signal.

Volume & Sentiment

  • Expected Volume Impact: Negligible. The transaction size is too small to impact trading volume.
  • Sentiment Indicator: Neutral. The market generally discounts sales made under 10b5-1 plans.

Additional Context

Special Circumstances

  • The filing explicitly states the sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2025. This allows insiders to set up a pre-determined trading schedule to avoid accusations of trading on non-public information.
Topics:#SECFiling#InsiderTrading#CSTL#CastleBiosciences#Form4#InsiderSell#StockMarket#Investing#10b51

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.